| Literature DB >> 31438522 |
Xiaojing Tian1,2, Tisong Liang1,2, Yuanlin Liu1,2, Gongtao Ding1, Fumei Zhang1,2, Zhongren Ma3,4.
Abstract
Lycium barbarum polysaccharides (LBPs), as bioactive compounds extracted from L. barbarum L. fruit, have been widely explored for their potential health properties. The extraction and structural characterization methods of LBPs were reviewed to accurately understand the extraction method and structural and biological functions of LBPs. An overview of the biological functions of LBPs, such as antioxidant function, antitumor activity, neuroprotective effects, immune regulating function, and other functions, were summarized. This review provides an overview of LBPs and a theoretical basis for further studying and extending the applications of LBPs in the fields of medicine and food.Entities:
Keywords: Lycium barbarum polysaccharides; antioxidant activity; antitumor activity; immune regulation; structural characterization
Mesh:
Substances:
Year: 2019 PMID: 31438522 PMCID: PMC6770593 DOI: 10.3390/biom9090389
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Figure 1The fresh (left) and dried form (right) of Lycium barbarum fruit.
Figure 2The flowchart of the extraction, purification, and analysis of Lycium barbarum polysaccharides (LBPs). WEM: water extraction method, EAM: enzyme-assisted extraction method, MAM: microwave-assisted extraction method, UAM: ultrasonic-assisted extraction method.
Summary of the extraction methods on the extraction of LBPs.
| Extraction Methods | Extraction Conditions | Yield (%) | Ref |
|---|---|---|---|
| Water extraction method | The ratio liquid to solid 70:1, pH 10, at 65 °C, extracted in soakage for 3.5 h. | 7.46–7.63% | [ |
| Ultrasound-assisted extraction method | Extraction time of 30 min, temperature of 60 °C, solid/liquid ratio of 20 g/600 mL, power density of 300 W/L, ultrasound frequency of 28 kHz. | 2.286–5.701% | [ |
| Enzyme-assisted extraction method | Extraction time of 91 min, extraction temperature of 59.7 °C, pH 5.0. | 6.81 ± 0.10 % | [ |
| Microwave-assisted extraction method | Ratio of water to raw material of 31.5 mL/g, extraction time of 25.8 min, microwave power of 544.0 W. | 8.25 ± 0.07% | [ |
| Combination of extraction methods | Temperature of 100 °C, extraction time of 53 min, liquid-to-solid ratio of 26 mL/g, ultrasonic electric power of 160 W. | 5.728% | [ |
The possible structure of repeat units, molecular weights, and analysis technique of polysaccharides in L. barbarum [39]. Definitions: SEC = size exclusive chromatography, GC–MS = gas chromatography–mass spectrometry, NMR = nuclear magnetic resonance, IR = infrared, GC = gas chromatography, ESI-MS = electrospray ionization mass spectrometry, HPGPC = high-performance gel permeation chromatography.
| No | Name | Mw (kDa) | Molar Ratio | Analysis Technique | Possible Structure of Repeat Unit | Ref |
|---|---|---|---|---|---|---|
| 1 | LbGp2 | 68,200 | Ara:Gal = 4:5 | SEC, GC-MS | Backbone composed of (1→6)- β-Gal. Branches composed of (1→3)- β-Ara and (1→3)- β-Gal terminated with (1 → 3)/(1→5)- α-Ara. | [ |
| 2 | LbGp3 | 92,500 | Ara:Gal = 1:1 | NMR | Backbone composed of (1→4)- β-Gal. Branches composed of (1→3)- β-Ara and (1→3)- α-Gal terminated with (1 → 3)/ (1→5)- α-Ara. | [ |
| 3 | LbGp4 | 214,800 | Ara:Gal:Rha:Glc = 1.5:2.5:0.43:0.23 | NMR | Backbone composed of (1→4)- β-Gal. Branches composed of (1→3)- β-Gal terminated with (1→3)- α-Ara and (1→3)- β-Rha. | [ |
| 4 | LBPA3 | 66,000 | Ara:Gal = 1.2:1 | Ion exchange chromatography | Heteropolysaccharide with (1→4), (1→6). | [ |
| 5 | LBPB1 | 18,000 | Ara:Glc = 1:3.1 | Heteropolysaccharide with (1→4), (1→6) β-glycosidic bond. | ||
| 6 | LBP-a4 | 10,200 | Fuc: gal = 0.41:1 | Ultrafiltration membrane method | [ | |
| 7 | LBPC2 | 12,000 | Xyl:Rha:Man = 8.8:2.3:1 | Heteropolysaccharide with (1→4), (1→6) β-glycosidic bond. | [ | |
| 8 | LBPC4 | 10,000 | Glc | IR, GC | Heteropolysaccharide with (1→4), (1→6) α-glycosidic bond. | [ |
| 9 | LBP1a-1 | 115,000 | Glc | α-(1→6)- D –glucan. | [ | |
| 10 | LBP1a-2 | 94,000 | Glc | α-(1→6)- D –glucan. | ||
| 11 | LBP3a-1 | 103,000 | GalA composed of a small amount of Gal and Ara | Gel permeation chromatography, NMR | Polygalacturonan with (1→4)- α-glycosidic bond. | |
| 12 | LBP3a-2 | 82,000 | GalA composed of a small amount of Gal and Ara | Polygalacturonan with (1→4)- α-glycosidic bond. | ||
| 13 | LBLP5-A | 113,300 | (1 -> 3)-linked Gal, (1 -> 4)-linked Gal, (1 -> 3)-linked Araf, (1 -> 5)-linked Araf, and (1 -> 2, 4)-linked Rhaf. | [ | ||
| 14 | WSP | Rha:Fuc:Ara:Xyl:Man:Gal:Glc = 1.6:0.2:51.4:4.8:1.2:25.9:7.3 | NMR, ESI-MS | Backbone composed of (1 → 2)-linked-Rha and (1→4)-linked-Gal. Branches composed of (1→5)-linked-Ara terminated with Ara residues, and (1→4)-linked-Xyl terminated with Man residues. | ||
| 15 | AGP | Rha:Ara:Xyl:Gal:Glc:GalA:GlcA = 3.3:42.9:0.3:44.3:2.4:7.0 | NMR | Backbone composed of linear homogalacturonan fragments and rhamnogalacturonan fragments. Side chains mainly composed of β−1,6- and β−1,4-galactopyranan and α−1,5-arabinofuranan. | [ | |
| 16 | LBP-IV | 41,800 | Rha:Ara:Xyl:Glc:Gal = 1.61:3.82:3.44: 7.54:1.00 | DEAE-Sephadex, HPGPC, IR, UV | Backbone composed of both α- and β- anomeric configurations of Ara and Glc. Rha was located at terminal of polysaccharide chain. | [ |
| 17 | LbGp1 | 49,100 | Ara:Gal = 5.6:1 | HPGPC | Backbone composed of (1→6)-Gal. Side chains mainly composed of (1→3)-Gal/(1→4)-Gal and (1→3)-Ara/(1→4)-Ara. Ara was located at terminal of branch. | [ |
| 18 | p -LBP | 64,000 | Fuc:Rha:Ara:Gal:Glc:Xyl:GalA:GlcA = 1.00:6.44:54.84:22.98:4.05: 2.95:136.98:3.35 | HPAEC-PAD, HPSEC, FT-IR, GC–MS, and NMR | Backbone composed of (1→4)- α-GalA. Side chains mainly composed of α−1,2- and α−1,4-Rha and α−1,5-Ara. | [ |
| 19 | LBP1B-S-2 | 80,000 | Rha:Ara:Gal:Glu = 3.13: 53.55: 39.37: 3.95 | DEAE Sepharose | Backbone consisted of 1, 3-linked beta-D-Galp, 1, 6-linked beta-D-Galp and branches contained 1, 4-linked beta-D-GlcpA, T-linked beta-D-Galp, 1, 6-linked beta-D-Galp, T-linked alpha-L-Araf, T-linked beta-L-Aral 1, 5-linked alpha-L-Araf and T-linked beta-L-Rhap. | [ |
| 20 | LRGP1 | 56,200 | Rha:Ara:Xyl:Man:Glu:Gal = 0.65:10.71:0.33:0.67:1:10.41 | HPGPC, ESI-MS | Backbone composed of (1 -> 3)-linked Gal. The branches were composed of (1 -> 5)-linked Ara, (1 -> 2)-linked Ara, (1 -> 6)-linked Gal, (1 -> 3)-linked Gal, (1 -> 4)-linked Gal and (1 -> 2,4)-linked Rha. | [ |
Antioxidant activity and mechanisms of LBPs.
| Antioxidant Activity | Mechanisms | Dose | Experiment Model | Experiment Type | Ref |
|---|---|---|---|---|---|
| Reduce oxidative stress | Regulating the level of MDA, SOD, GSH | 100, 200, and 400 mg/kg | Rats | In vivo | [ |
| Against hypoxia-induced injury | Down-regulation of miR-122 | 300 mu g/mL | Cells | In vitro | [ |
| Reduces hyperoxic acute | Induced activation of Nrf2 | 100 mg/kg | Mice | In vivo | [ |
| Attenuates diabetic testicular dysfunction | Upregulated p-PI3K and p-Akt protein expressions | 40 mg/kg | Mice | In vivo | [ |
| Radical scavenging | Free radical scavenging | IC 50:1.29–3.00 mg/mL(DPPH) 0.39–1.10 mg/mL (ABTS) | Chemical reagent | In vivo | [ |
| Regulate the activity of enzymes | Increased activity of antioxidative enzymes | 200–400 mg/kg | Rats | In vivo | [ |
Immune regulation activity and mechanisms of LBPs.
| Immune Regulation Activity | Mechanism | Experiment Type | Ref |
|---|---|---|---|
| Enhanced macrophage endocytic and phagocytic capacities in vivo | Activate transcription factors NFAT, AP-1, prompt CD25 expression, induce IL-2 and IFN-gamma gene transcription and protein secretion | In vitro | [ |
| Regulation of immune cells | Maintain high levels of T cells, prevent the increase of Tregs, promote infiltration of CD8+ T cells | In vivo | [ |
| Induce the phenotypic and functional maturation of DCs | Upregulate the expression of Notch and Jagged and Notch targets Hes1 and Hes5 | In vitro | [ |
| Promote the proliferation of spleen cells | Increase secretion of INF-alpha and IL-6, mRNA expression of iNOS, IL-beta and IL-6 through activating phosphorylation of ERIC, JNK, p38 and p65 | In vitro | [ |
| Increased immune organ indexes | Promote blood B and T lymphocyte proliferation | In vivo | [ |
| Improve immune responses | Stimulate CD4(+) and CD8(+) T cell proliferation | In vitro | [ |
| Enhance the immune activity | Enhance PCV2-specific IgG antibody responses, promote Th1 cytokines (IFN-gamma and TNF-alpha) and Th2 cytokine (IL-4) secretion | In vitro | [ |
| Enhance the immune activity | Inhibit cell proliferation, retard cell cycle growth, and promote apoptosis | In vitro, In vivo | [ |
Antitumor activities and mechanism of LBPs.
| Antitumor Activity | Mechanism | Tumor Model | Experiment Type | Ref |
|---|---|---|---|---|
| Reduce cell viability | Inhibit growth of tumor | MCF-7, T47D, SMMC-7721, DU145 | In vitro | [ |
| Regulate apoptosis | Induce apoptosis | MCF-7, BIU87 | In vitro | [ |
| Regulate cell cycle | Arrest the cells at the G1 phase | SW480, Caco-2 cells | In vitro | [ |
| Regulate immune activity | Enhance immunity | Mice | In vivo | [ |
Neuroprotective effects and mechanisms of LBPs.
| Neuroprotection Effects | Molecular Mechanism | Experiment Type | Ref |
|---|---|---|---|
| Improve neurodegenerative diseases | Increase the activity of Akt; regulate the expression of HSP60/HSP70; reduce caspase cascade reaction | In vitro, In vivo | [ |
| Inhibition of oxidative stress | Increase SOD, CAT and GSH-Px; decrease the ROS level, inhibit JNK pathway | In vitro, In vivo | [ |
| Inhibition of inflammation | Inhibit of NF-κB | In vivo | [ |
| Inhibit abnormal differentiation of nerve cells | Increase differentiation of hippocampal neuron stem cells and inhibit abnormal differentiation | In vitro | [ |
| Inhibition of apoptosis | Promotes Bcl-2, inhibits Bax, overexpression of CytC gene | In vivo | [ |
| Reduce glutamate toxicity | Decrease neurotoxic effects of glutamate on PC12 cells; inhibition of ROS accumulation, LDH release and Ca[2]+ overload | In vivo | [ |
| Inhibit the tube formation of microvascular endothelial cells | No report | In vivo | [ |
| Neuroprotective agent in ischaemic retinopathies | Enhance immunoreactivity of protein kinase C alpha and attenuated glial fibrillary acidic protein expression | In vivo | [ |
Other biological activities and mechanism of LBPs.
| Biological activities | Mechanism | Experiment type | Ref |
|---|---|---|---|
| Attenuates diabetic testicular dysfunction | Inhibition of the PI3K/Akt pathway-mediated abnormal autophagy | In vivo | [ |
| Inhibit the vascular lesions | Regulating p38MAPK signaling pathways, inhibiting absorption of glucose | In vivo | [ |
| Prevents against ultraviolet-induced damage | Activation of Nrf2 | In vivo | [ |
| Protect the liver from hepatotoxicity | Regulating oxidative stress | In vivo | [ |
| Alleviating effects of CCl4-induced liver fibrosis | Inhibition of the TLRs/NF-kappa B signaling pathway expression | In vivo | [ |
| Alleviating dry-eye disease | Schirmer’s test, tear break-up time (BUT) measurement | In vivo | [ |
| Protects against neurotoxicity | Upregulating Nrf2/HO-1 signaling | In vitro | [ |
| Ameliorate Cd testicular damage | Regulate oxidative stress | In vivo | [ |